Adicet Bio, Inc. — Director's Dealing 2024

Aug 23, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2024-08-21

Reporting Person: GORDON CARL L (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-21	Stock Option (Right to Buy)	$2.14	D	30000	Disposed	2030-09-16	Common Stock (30000)	Direct
2024-08-21	Stock Option (Right to Buy)	$16.11	A	30000	Acquired	2030-09-16	Common Stock (30000)	Direct
2024-08-21	Stock Option (Right to Buy)	$2.14	D	18500	Disposed	2031-04-29	Common Stock (18500)	Direct
2024-08-21	Stock Option (Right to Buy)	$15.93	A	18500	Acquired	2031-04-29	Common Stock (18500)	Direct
2024-08-21	Stock Option (Right to Buy)	$2.14	D	18500	Disposed	2032-06-01	Common Stock (18500)	Direct
2024-08-21	Stock Option (Right to Buy)	$11.49	A	18500	Acquired	2032-06-01	Common Stock (18500)	Direct
2024-08-21	Stock Option (Right to Buy)	$2.14	D	26400	Disposed	2033-05-31	Common Stock (26400)	Direct
2024-08-21	Stock Option (Right to Buy)	$5.195	A	26400	Acquired	2033-05-31	Common Stock (26400)	Direct

Footnotes

F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2: The shares subject to this option are fully vested and exercisable as of the date hereof.